Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 19/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177644 | 1.00 | ADORA1 (0.59) | ADORA1SLC6A3RET | |
| SCHEMBL1177034 | 0.90 | ADORA1 (0.72) | ADORA1SLC6A3RET | |
| SCHEMBL1177172 | 0.86 | ADORA1 (0.59) | ADORA1SLC6A3RET | |
| SCHEMBL1177173 | 0.86 | ADORA1 (0.59) | ADORA1SLC6A3RET | |
| SCHEMBL8011126 | 0.84 | ADORA1 (0.56) | ADORA1SLC6A3RET | |
| SCHEMBL1930760 | 0.83 | ADORA1 (0.65) | ADORA1SLC6A3 | |
| SCHEMBL1930758 | 0.83 | ADORA1 (0.65) | ADORA1SLC6A3 | |
| SCHEMBL12536118 | 0.79 | ADORA1 (0.58) | ADORA1SLC6A3 | |
| SCHEMBL12869964 | 0.77 | ADORA1 (0.71) | ADORA1SLC6A3RET | |
| SCHEMBL8019184 | 0.76 | ADORA1 (0.56) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618119-B2 | Fused cyanopyridines and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | Bayer Schering Pharma (DE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | TNNI3, QDPR, RYR2 | ADORA1 2751/4885SLC6A3 2984/4885RET 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.